Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 13/20 | 0.58 |
| ▸ | KCNQ2 | O43526 | 13/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704262 | 0.93 | KCNQ3 (0.56) | KCNQ3KCNQ2KMT2AMAPK14NPC1 | |
| SCHEMBL3702539 | 0.90 | KCNQ3 (0.52) | KCNQ3KCNQ2KMT2AALDH1A1 | |
| SCHEMBL3700376 | 0.89 | KCNQ2 (0.55) | KCNQ3KCNQ2KMT2ACACNA1GCACNA1H | |
| SCHEMBL3705629 | 0.88 | KCNQ3 (0.55) | KCNQ3KCNQ2KMT2ANPC1RAB9A | |
| SCHEMBL3703085 | 0.86 | KCNQ3 (0.52) | KCNQ3KCNQ2KMT2AALDH1A1 | |
| SCHEMBL3703285 | 0.86 | KCNQ3 (0.53) | KCNQ3KCNQ2KMT2AMAPK14MEN1 | |
| SCHEMBL3698144 | 0.85 | KCNQ3 (0.53) | KCNQ3KCNQ2 | |
| SCHEMBL6126263 | 0.84 | KCNQ3 (0.50) | KCNQ3KCNQ2 | |
| SCHEMBL3703211 | 0.84 | KCNQ3 (0.54) | KCNQ3KCNQ2KMT2AALDH1A1 | |
| SCHEMBL3703448 | 0.83 | KCNQ3 (0.65) | KCNQ3KCNQ2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | claimed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122888-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNJ2 | KCNQ3 4/4885KCNQ2 2/4885KMT2A 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.